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Introduction: Neuregulin 1 (NRG1) has been discovered as the tail 
moiety of fusion genes with several distinct partner head genes in 
lung cancers. These fusion genes activate ERBB2/ERBB3 receptor-
mediated cell signaling and thereby function as oncogenic drivers.
Methods: We have carried out whole-transcriptome sequencing of 
100 non–small-cell lung carcinoma tumors and isolated a novel fusion 
gene consisting of vesicle-associated membrane protein 2 (VAMP2) and 
NRG1. Reverse transcription-polymerase chain reaction and genomic 
DNA analysis were used to demonstrate interchromosomal translocation. 
Immunoblotting and soft agar assays were used to examine stimulating 
activity of the fusion gene through ERBB2/ERBB3 signaling pathway.
Results: The most highly expressed splice variant of VAMP2–NRG1 
fusion gene was shown to be membrane bound and display EGF-like 
domain of NRG1 extracellularly. VAMP2–NRG1 promotes anchor-
age-independent colony formation of H1568 lung adenocarcinoma 
cells. Ectopic expression of the fusion gene stimulates phosphoryla-
tion of ERBB2 and ERBB3 as well as downstream targets, AKT and 
ERK, confirming activation of the signaling pathway.
Conclusion: VAMP2–NRG1 is a novel oncogenic fusion gene rep-
resenting a new addition to the list of NRG1 fusion genes, which 
together may form an important diagnostic and clinical category of 
lung adenocarcinoma cases.
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Fusion genes represent an important class of oncogenes. In lung cancers, fusion genes containing anaplastic lym-
phoma kinase (ALK),1,2 RET tyrosine kinase,3 and ROS1 
tyrosine kinase4 as tail genes have been found. Interestingly, 
multiple head fusion partners have been found for these 
kinases establishing a paradigm in which a common over-
expressed or dysregulated tail gene partner with multiple 
head genes promotes oncogenesis presumably through 
a common mechanism. Another similar case is the fusion 
oncogenes containing neuregulin 1 (NRG1), a ligand gene 
for ERBB2/ERBB3 receptor tyrosine kinase complex.5 The 
first reported case involving NRG1 was in breast cancer cell 
line MDA-MB-175 in which the partner was DOC4.6 In lung 
cancers, fusion genes of NRG1 have been reported with 
multiple partners including CD74, SLC3A2, RBPMS, and 
SDC4.7–9 Here, we report identification of vesicle-associated 
membrane protein 2 (VAMP2)–NRG1 in an non–small-cell 
lung carcinoma (NSCLC) case and characterization of its 
function in ERBB2/ERBB3 signaling.
MATERIALS AND METHODS
Tumor and neighboring normal tissue samples were 
obtained from lung cancer patients who had undergone cura-
tive surgery. Samples were collected with written informed 
consents from patients and the approval of the institutional 
review boards. RNA extraction, cDNA synthesis, and high-
throughput sequencing have been carried out as previously 
described10 with minor modifications. Reverse transcription-
polymerase chain reaction (RT-PCR) and Sanger sequencing 
were carried out following conventional protocols. To map 
the fusion point in the genomic DNA, long amplification Taq 
DNA polymerase (Takara Bio, Otsu, Japan) was utilized. To 
predict fusion transcripts, RNA-seq data were processed using 
FusionScan program (http://fusionscan.ewha.ac.kr) as previ-
ously described.10 To identify the expressed splice variants, 
multiple primers from NRG1 exons were used in combina-
tion with a common 5′ primer from VAMP2 to amplify cDNA 
from tumor tissues. We also used primary RNA-seq data to 
quantify expression of individual exons (see Supplementary 
Fig., Supplemental Digital Content 1, http://links.lww.com/
JTO/A833). To generate retroviruses expressing VAMP2– 
NRG1-I-β3 or VAMP2–NRG1-I-γ, the coding region of 
fusion gene was amplified from tumor and subcloned into the 
LZRS retroviral vector plasmid (pLZRS) along with internal 
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ribosome entry site-green fluorescent protein (IRES-GFP) as 
previously described.11 The control virus contained just the 
IRES-GFP in pLZRS. Production of high titer virus prepa-
ration in 293GPG cells was carried out as described with 
minor modifications.11 For live staining, anti-V5 antibody was 
applied in the culture medium directly. H1568 cells were cul-
tured in RPMI1640 with 10% fetal bovine serum (Hyclone, 
Logan, UT). Antibodies used for immunoblotting are listed 
(see Supplementary Table, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A833). For soft agar assays, 1 × 104 
(per 21 mm dish) retrovirus-transduced H1568 cells were sus-
pended in 0.5% agar containing culture medium and overlaid 
onto a 1.2% agar containing culture medium. Colonies were 
stained after 21 days with 3-(4,5-Dimethylthiazol-2-Yl)-2,5-
Diphenyltetrazolium Bromide (MTT) solution, and colony 
numbers were determined using Gel Doc XR system with 
Quantity One 1-D analysis software. Detailed protocols for all 
procedures and sequences of oligonucleotide primers used for 
RT-PCR and cloning are available upon request.
RESULTS
We have carried out RNA-seq analyses of matched nor-
mal and tumor samples from more than 100 NSCLC cases. 
Detailed results will be published elsewhere, and sequencing 
data will be posted on http://ercsb.ewha.ac.kr/labkm. Two 
fusion genes containing NRG1 as the tail gene were identi-
fied. One of them was fused with CD74 with the identical 
structure to the previously reported case.7,8 The novel fusion 
gene VAMP2–NRG1 was found from a 67-year-old never-
smoker female adenocarcinoma patient with no mutations in 
EGFR, KRAS, and BRAF and with no fusion genes involv-
ing ALK, ROS1, or RET. Analysis of RNA-seq data shows 
multiple sequence reads mapping across the fourth exon of 
VAMP2 and fifth exon of NRG1 (Fig. 1A). The presence of 
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FIGURE 1. A, Alignment of sequence 
reads mapping to vesicle-associated 
membrane protein 2 (VAMP2) and 
Neuregulin 1 (NRG1) from RNA-seq 
data. The sequence of the assembled 
fusion transcript appears at the top, 
and individual reads are below. The 
vertical line indicates the fusion point. 
Sequences to the left matches Exon 
4 of VAMP2 and to the right matches 
Exon 5 of NRG1. B, A schematic of 
fusion genes with exons from VAMP2 
and NRG1. Expected RT-PCR product 
is seen only from tumor (T) but not 
adjacent normal (N) tissues. Sequence 
traces from Sanger sequencing show 
the nucleotides around the exon–exon 
boundary.
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fusion transcript in the tumor but not in normal tissue was 
confirmed by conventional RT-PCR and Sanger sequencing 
(Fig. 1B and C). We also applied long distance PCR technol-
ogy to amplify and sequence the portion of genomic DNA 
that spans the fusion (the fifth exon of VAMP2 and fourth 
intron of NRG1) site thus demonstrating the interchromo-
somal translocation (see Supplementary Fig., Supplemental 
Digital Content 3, http://links.lww.com/JTO/A833). Of note, 
this fusion is distinct from CD74–NRG1 and SLC3A2–NRG1 
in that the latter two show NRG1 portions starting from the 
ninth exon.
NRG1 has multiple splice variants. NRG1 portions 
in all CD74–NRG1 and SLC3A2–NRG1 fusion cases thus 
far reported had the form of the variant I-β3. We found 
that virtually all NRG1 fusion transcripts from our RNA-
seq data also could be aligned with this splice variant. We 
were also able to detect this transcript readily by RT-PCR 
but had to carry out nested PCR for others. The projected 
VAMP2–NRG1-I-β3 is a transmembrane protein with the 
EGF-like domain in the extracellular compartment (Fig. 
2A). Two retroviral constructs of fusion genes were gener-
ated with NRG1 portions of splice variants I-β3 and I-γ and 
used to infect H1568 lung adenocarcinoma cells. We con-
firmed the projected orientation of the EGF-like domain by 
live staining for V5 epitope in the C-terminus (Fig. 2B). We 
also examined the expression of VAMP2 portion and found 
that they were found in the cytoplasmic compartment (see 
Supplementary Fig., Supplemental Digital Content 4, http://
links.lww.com/JTO/A833).
NRG1-I-β3 functions as a ligand for ERBB2/ERBB3 
receptor complex through the EGF-like domain, which the 
NRG1-I-γ splice variant lacks. We examined the activation of 
the components of the ERBB signaling cascade after the infec-
tion of the control and NRG1 viruses. Consistent with that 
VAMP2–NRG1-I-β3 activates the signaling pathway, phos-
phorylation of ERBB2, ERBB3, AKT, and ERK was increased 
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FIGURE 2. A, Schematic illustra-
tions of vesicle-associated membrane 
protein 2 (VAMP2)–Neuregulin 1-I-β3 
(NRG1-I-β3) (left) and VAMP2–
NRG1-I-γ (right) proteins. Note that 
the trans-membrane is provided by 
VAMP2 and that V5 epitope is in the 
C-terminus of each protein. B, Live 
V5 staining images of H1568 cells 
after retroviral transduction. Top row 
panels show control virus-infected 
cells with only green fluorescent pro-
tein (GFP) signal. Middle row panels 
and bottom row panels show cells 
infected, respectively, with VAMP2–
NRG1-I-β3 and VAMP2–NRG1-I-γ. 
Note V5 staining in GFP positive cells.
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(Fig. 3A). This was in contrast to what was seen with the infec-
tion of the control and VAMP2–NRG1-I-β3 viruses. We next 
performed the soft agar assay to see if VAMP2–NRG1-I-β3 
promotes anchorage independent growth using H1568 cells, 
which are capable of minimal growth without adhering to 
plastic dishes. Indeed, a significant increase in the number and 
size of the colonies was seen with the VAMP2–NRG1-I-β3 
compared with the other two viruses. This indicates that the 
VAMP2–NRG1 fusion gene, in particular its most dominant 
splice variant, is capable of promoting cellular growth and 
thus likely functions as an oncogene.
DISCUSSION
Large-scale high throughput sequencing data are pro-
viding new candidates for oncogenes and tumor suppressors 
of NSCLC. Prominent among these are fusion genes with 
oncogenic tail genes in combination with multiple head genes. 
NRG1 fusion genes seem to be one such case, as multiple head 
partners have been found in a variety of cancers. Interestingly, 
at least three cases involving CD74, SLC3A2, and VAMP2 fea-
ture transmembrane domain provided by the head gene and 
NRG1 portion matching the splice variant I-β3 with the EGF-
like domain in the extracellular compartment.7,8 In another 
reported case, the promoter of WRN is fused to NRG1 leav-
ing the whole NRG1 coding region intact thereby presumably 
allowing production of a transmembrane protein.9 It is pos-
sible that additional NRG1 fusion genes with similar struc-
tures may be added to the list in the future and collectively 
occupy a significant portion of driver mutations of NSCLC. 
It should be noted that NRG1 fusion genes with no apparent 
transmembrane domain have also been reported.9 Whether 
these fusion genes also have oncogenic function remains to 
be addressed. Importantly, the splice variant I-γ which differs 
from the variant I-β3 only for the lack the EGF-like domain, 
could not activate ERBB2/ERBB3 signaling or stimulate 
anchorage independent growth. This strongly suggests that 
the EGF-like domain functions as the oncogenic ligand for 
ERBB2/ERBB3 receptor complex, and that this interaction 
may be targeted for therapeutic intervention for NRG1-fusion 
driven carcinogenesis.
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